Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility. The increased capability to flexibly manufacture ...
read more
Tuesday, January 04, 2022
Curia, formerly AMRI, has unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for ...
read more
Wednesday, September 22, 2021
CuriRx, Inc., a leading contract research (CRO) and product development organization, announced the launch of their new CuriLytics™ platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Led by CuriRx's team of ...
read more
Curis has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. As previously reported, the extension of exclusivity is associated with a payment of $7....
read more
Tuesday, November 17, 2020
Curis has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI, a component of the National Institutes of Health.
read more
Curium Pharma, a provider of nuclear medicine services, announces the successful completion of its acquisition of Eczacibasi-Monrol Nuclear Products Co. (Monrol), a prominent player in nuclear medicine based in Istanbul, Turkey.
read more
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA).
read more
Tuesday, September 20, 2016
Custom Pharma Services, a full-service contract development and manufacturing organization (CDMO), has acquired a new building to expand its high containment manufacturing and development operations.
read more
A California dietary supplement manufacturer recently was ordered by a federal court to stop selling its products until the company comes into compliance with the FDA’s dietary supplement manufacturing regulations and other requirements listed in a ...
read more
Wednesday, January 04, 2017
Custopharm, Inc. has acquired two paragraph IV abbreviated new drug application (ANDA) products from Perrigo Company.
read more
Tuesday, November 15, 2016
CutisPharma has announced the opening of a Research and Development center to house the company's expanding R&D team. The new center will provide office and laboratory space to facilitate the company's aggressive plans for developing products for FDA...
read more
Wednesday, August 05, 2015
Pricey specialty drugs helped CVS Health cope with tobacco withdrawal and top analyst expectations in the second quarter.
read more
CVS Health today announced its new Clinical Trial Services business that brings together innovation and experience to drive greater access to clinical trials across the communities it serves and create a more efficient, convenient experience to ...
read more
Wednesday, March 30, 2022
CVS Health has entered into an agreement with the State of Florida to resolve claims dating back more than a decade related to prescriptions for opioid medications that were filled at Florida CVS Pharmacy locations.
read more
CyanVac announced they have selected Exothera for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector.
read more